急诊科启动丁丙诺啡治疗阿片类物质使用障碍:一项随机临床试验
这项在美国29个急诊科开展的多中心随机临床试验纳入2000例未经治疗的阿片类物质使用障碍成人患者(COWS评分≥4),比较急诊启动7天长效注射丁丙诺啡与舌下丁丙诺啡对第7天治疗参与率的影响。结果显示两组第7天参与率无显著差异(40.5% vs 38.5%,校正差值1.6%,95%CI -2.8%至6.0%),长效注射组渴求评分更低、非法阿片使用天数更少、治疗满意度更高,两组耐受性均良好, precipitated withdrawal罕见。
要点
- 急诊启动7天长效注射丁丙诺啡与舌下丁丙诺啡第7天治疗参与率无显著差异。
- 长效注射组第7天渴求评分更低(26.5 vs 30.2),非法阿片使用天数更少,满意度更高。
- 两组precipitated withdrawal均罕见(0.6% vs 0.8%),30天内过量事件各2.3%。
核心结论
- 第7天阿片类物质使用障碍治疗参与率在7天长效注射丁丙诺啡组与舌下丁丙诺啡组之间未检测到差异。
- 两种丁丙诺啡制剂均耐受良好,尽管芬太尼阳性率高,precipitated withdrawal罕见。
研究设计与样本
- 多中心随机临床试验,纳入美国29个急诊科就诊的未经治疗的阿片类物质使用障碍成人患者,COWS评分≥4,招募时间2020年7月12日至2024年8月21日,最终随访于2024年10月24日完成。
- 随机分组后排除6例重复入组患者,最终长效注射组991例、舌下组1003例。
- 干预为24 mg长效注射丁丙诺啡(相当于16 mg/d)或舌下丁丙诺啡(COWS<8时自我给药指导,COWS≥8时急诊给予8 mg舌下丁丙诺啡),所有舌下组患者接受7天16 mg/d处方,两组均转介7天内预约持续药物治疗。
主要发现
- 第7天治疗参与率长效注射组40.5% vs 舌下组38.5%(校正差值1.6%,95%CI -2.8%至6.0%)。
- 第30天治疗参与率长效注射组43.8% vs 舌下组44.9%(校正差值-1.5%,95%CI -6.2%至3.2%)。
- precipitated withdrawal发生率长效注射组6例(0.6%)vs 舌下组8例(0.8%);30天内过量事件两组各18例(2.3%)。
- 第7天渴求评分(量表0-100)长效注射组均值26.5 vs 舌下组30.2(校正均值差-3.85,95%CI -7.08至-0.63)。
- 过去7天非法阿片使用天数校正均值比0.77(95%CI 0.68-0.95),治疗满意度评分(量表1-5)校正均值差0.13(95%CI 0.01-0.25),均有利于长效注射组。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Extended-release injectable buprenorphine may expand the reach of initiating medications for opioid use disorder in high-risk and hard-to-reach individuals who visit the emergency department (ED) and can be administered in low levels of withdrawal. OBJECTIVE: To compare the effect of ED-initiated 7-day extended-release injectable buprenorphine vs sublingual buprenorphine on treatment engagement at 7 days. DESIGN, SETTING, AND PARTICIPANTS: Multicenter randomized clinical trial enrolling adult patients presenting to the ED with untreated opioid use disorder and a Clinical Opiate Withdrawal Scale (COWS) score of 4 or higher across 29 EDs in the US from July 12, 2020, to August 21, 2024. Final follow-up was completed on October 24, 2024. INTERVENTIONS: Patients were randomized to receive a 24-mg injection of extended-release buprenorphine (equivalent to 16 mg/d) or sublingual buprenorphine, which included either self-administration instructions if the COWS score was less than 8 or administration of 8 mg of sublingual buprenorphine in the ED if the COWS score was 8 or higher. All sublingual buprenorphine group patients received a 7-day prescription for 16 mg/d. Both groups were provided referral for ongoing medication with a scheduled appointment within 7 days. MAIN OUTCOMES AND MEASURES: Engagement in opioid use disorder treatment on day 7 was the primary outcome. Secondary outcomes included engagement at 30 days, precipitated withdrawal and overdose events, craving scores, days of illicit opioid use, and patient satisfaction with treatment. RESULTS: Among 2000 patients randomized, 6 who were enrolled twice were excluded, resulting in 991 in the extended-release group and 1003 in the sublingual group. The median age was 37 (IQR, 30-47) years, 68% were male, 31% had an initial COWS score of 4 to 7, and 76% tested positive for fentanyl. The adjusted proportion of engagement in opioid use disorder treatment at 7 days was 40.5% with extended-release buprenorphine vs 38.5% with sublingual buprenorphine (adjusted difference, 1.6%; 95% CI, -2.8% to 6.0%). Engagement at 30 days was similar, with adjusted proportions of 43.8% with extended-release buprenorphine vs 44.9% with sublingual buprenorphine (adjusted difference, -1.5%; 95% CI, -6.2% to 3.2%). Precipitated withdrawal was rare: 6 (0.6%) with extended-release buprenorphine and 8 (0.8%) with sublingual buprenorphine. Overdose events within 30 days occurred in 18 participants (2.3%) in each group. Patients receiving extended-release buprenorphine reported lower mean craving scores at 7 days vs those receiving sublingual buprenorphine (scale, 0-100; mean score, 26.5 vs 30.2, respectively; adjusted mean difference, -3.85; 95% CI, -7.08 to -0.63), fewer days of illicit opioid use in the past 7 days (adjusted ratio of means, 0.77; 95% CI, 0.68-0.95), and better treatment satisfaction scores (scale, 1-5; adjusted mean difference, 0.13; 95% CI, 0.01-0.25). CONCLUSIONS AND RELEVANCE: No difference was detected in opioid use disorder treatment engagement on day 7 between the 7-day extended-release and sublingual buprenorphine groups. Both buprenorphine formulations were well tolerated; precipitated withdrawal was rare despite a high prevalence of fentanyl. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04225598.
引用
- D'Onofrio G, Herring AA, Hawk KF, et al. Emergency Department-Initiated Buprenorphine for Opioid Use Disorder: A Randomized Clinical Trial. JAMA. 2026. PMID: 41670966. doi:10.1001/jama.2025.27019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。